Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma

dc.contributor.authorRodríguez-Martínez, Carlos E.
dc.contributor.authorSossa-Briceño, Mónica P.
dc.contributor.authorCastro-Rodriguez, Jose A.
dc.date.accessioned2020-08-11T20:19:55Z
dc.date.available2020-08-11T20:19:55Z
dc.date.issued2013
dc.description.abstractenglishIntroduction. The choice among the different treatments available can have a great impact on the costs of asthma, Objectives. The objective of this study was to estimate the incremental cost-utility ratio of three inhaled corticosteroids (ICs): budesonide (BUD), fluticasone propionate (FP), and ciclesonide, compared to beclomethasone dipropionate (BDP) (the only IC included in the Compulsory Health Insurance Plan of Colombia), Methods. A Markov-type model was developed to estimate costs and health outcomes of a simulated cohort of patients less than 18 years of age with persistent asthma treated over a 12-month period. Effectiveness parameters were obtained from a systematic review of the literature. Cost data were obtained from a hospital´s bills and from the national manual of drug prices. The study assumed the perspective of the national healthcare in Colombia. The main outcome was the variable “quality-adjusted life years” (QALY), Results. While treatment with BDP was associated with the lowest cost (£106.16 average cost per patient during 12 months), treatment with FP resulted in the greatest gain in QUALYs (0.9325 QALYs). FP was associated with a greater gain in QALYs compared to BUD and ciclesonide (0.9325 vs. 0.8999 and 0.9051 QALYs, respectively) at lower costs (£231.19 vs. £309.27 and £270.15, respectively), thus leading to dominance. The incremental cost-utility ratio of FP compared to BDP was £19,835.28 per QALY, Conclusions. BDP is the most cost-effective therapy for treating pediatric patients with persistent asthma when willingness to pay (WTP) is less than £21,129.22/QALY, otherwise, FP is the most cost-effective therapy.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.3109/02770903.2013.767909
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1532-4303
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlhttps://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/3762
dc.language.isoeng
dc.publisherTaylor and Francisspa
dc.publisher.journalJournal of Asthmaspa
dc.relation.ispartofseriesJournal of Asthma, 1532-4303, Vol. 50, Nro. 4, 2013, p. 410-418spa
dc.relation.urihttps://www.tandfonline.com/doi/full/10.3109/02770903.2013.767909
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2013-03-05
dc.rights.localAcceso abiertospa
dc.subject.keywordsAsthmaspa
dc.subject.keywordsChildrenspa
dc.subject.keywordsCost-effectivenessspa
dc.subject.keywordsDeveloping countriesspa
dc.subject.keywordsInhaled corticosteroidsspa
dc.subject.keywordsQuality adjusted life yearsspa
dc.titleCost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthmaspa
dc.title.translatedCost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthmaspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Rodríguez-Martínez, Carlos E..pdf
Tamaño:
668.46 KB
Formato:
Adobe Portable Document Format
Descripción:
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:

Colecciones